Condition (MeSH)
Factor VII Deficiency
ClinicalTrials.gov lists 11 trials for Factor VII Deficiency or a narrower condition beneath it.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
11 of the 11 trials are tagged with Factor VII Deficiency itself; the rest are tagged with a narrower condition beneath it.
When did Factor VII Deficiency trials start? (9)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 3
- Not applicable
- Observational
Top of scale: 2
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 2 |
| 2025 | 1 |
| 2024 | 2 |
| 2022 | 1 |
| 2021 | 1 |
| 2018 | 1 |
| 2017 | 1 |
| 2016 | 1 |
| 2007 | 1 |
No forecast is made for this condition: it averages 1.2 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 3 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Factor VII Deficiency trials in? (6)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 2 |
| Phase 1/2 | 2 |
| Phase 2 | 2 |
| Phase 3 | 1 |
| Not applicable | 1 |
| Observational | 3 |
How many Factor VII Deficiency trials are recruiting? (6)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 1 |
| Recruiting | 3 |
| Enrolling by invitation | 1 |
| Active, not recruiting | 1 |
| Completed | 4 |
Showing 5 of 6 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Factor VII Deficiency trials? (6)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| AryoGen Pharmed Co. | 2 |
| Shanghai RAAS Blood Products Co., Ltd. | 2 |
| Catalyst Biosciences | 1 |
| Equilibra Bioscience LLC | 1 |
| Hangzhou Gensciences Biopharmaceutical Co., Ltd. | 1 |
Showing 5 of 6 sponsors.
Which drugs are being tested for Factor VII Deficiency? (3)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| activated recombinant human factor VII | 2 |
| Sutacimig | 1 |
| Fresh Frozen Plasma | 1 |
Interventions as named in the registry (7)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| SR604 | 3 |
| Coagulation Factor VIIa variant | 1 |
| Eptacog alfa, biosimilar | 1 |
| Activated Prothrombin Complex Concentrates | 1 |
| Virus Inactivated plasma | 1 |
Showing 5 of 7 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which publications cover Factor VII Deficiency? (9)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| A multicenter, observational study to evaluate hemostasis following recombinant activated FVII treatment in patients in Japan with congenital factor VII deficiency. | Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis | 2023 | Yes |
| Pharmacokinetic properties of recombinant FVIIa in inherited FVII deficiency account for a large volume of distribution at steady state and a prolonged pharmacodynamic effect. | Thrombosis and haemostasis | 2014 | Yes |
| Prophylaxis in congenital factor VII deficiency: indications, efficacy and safety. Results from the Seven Treatment Evaluation Registry (STER). | Haematologica | 2013 | Yes |
| Invasive procedures and minor surgery in factor VII deficiency. | Haemophilia : the official journal of the World Federation of Hemophilia | 2012 | Yes |
| Recombinant, activated factor VII for surgery in factor VII deficiency: a prospective evaluation - the surgical STER. | British journal of haematology | 2011 | Yes |
Showing 5 of 9 publications.
Prevalence (2)
Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.
| Orphanet disease | Type | Class | Geography | Jurisdiction | Mapping relation |
|---|---|---|---|---|---|
| Congenital factor VII deficiency | Point prevalence | 1-9 / 1 000 000 | Europe | Not stated | Exact |
| Congenital factor VII deficiency | Point prevalence | 1-9 / 1 000 000 | Europe | Not stated | Exact |
Rare-disease identity (2)
Shown in this order: exact, broader, narrower, other.
| Orphanet disease | ORPHA code | Relation | Source |
|---|---|---|---|
| Congenital factor VII deficiency | 327 | Exact | Orphanet Rare Disease Ontology (ORDO) |
| Congenital factor VII deficiency | 327 | Exact | Orphadata Science knowledge files, Product 1 |
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: serious adverse events in this condition's trials and sub-conditions in mesh.